Create Medicines raises $122M to bolster in vivo CAR-T therapies
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.